KNApSAcK Metabolite C00032769
Metabolite
KNApSAcK Entry
| id | C00032769 |
|---|---|
| Name | bis-Demethoxycurcumin / bis-(4-hydroxycinnamoyl)methane / p,p'-Dihydroxydicinnamoyl methane |
| CAS RN | 24939-16-0 |
| Standard InChI | InChI=1S/C19H16O4/c20-16-7-1-14(2-8-16)5-11-18(22)13-19(23)12-6-15-3-9-17(21)10-4-15/h1-12,20-21H,13H2/b11-5+,12-6+ |
| Standard InChI (Main Layer) | InChI=1S/C19H16O4/c20-16-7-1-14(2-8-16)5-11-18(22)13-19(23)12-6-15-3-9-17(21)10-4-15/h1-12,20-21H,13H2 |
Cluster
| Phytochemical cluster | |
|---|---|
| KCF-S cluster | No. 2164 |
Link
ChEMBL
| By standard InChI | CHEMBL105350 |
|---|---|
| By standard InChI Main Layer | CHEMBL105350 |
KEGG
| By LinkDB | C17743 |
|---|
CTD
| By CAS RN | C034786 |
|---|
Species
Summary
Plant class
| class name | count |
|---|---|
| Liliopsida | 3 |
Family
| family name | count |
|---|---|
| Zingiberaceae | 3 |
List (3)
* NCBI
| KNApSAcK organism | *ID | *family | *plant class | *kingdom |
|---|---|---|---|---|
| Curcuma chuanyujin | 136212 | Zingiberaceae | Liliopsida | Viridiplantae |
| Curcuma longa L. | 136217 | Zingiberaceae | Liliopsida | Viridiplantae |
| Curcuma zedoaria ROSCOE | 99568 | Zingiberaceae | Liliopsida | Viridiplantae |
Human Protein / Gene in interaction
4 ChEMBL Protein in interactions
| accession | description | class description | compound | assay ID (# of activities) |
# of diseases
(OMIM / KEGG) |
|---|---|---|---|---|---|
| P35354 | Prostaglandin G/H synthase 2 | Oxidoreductase | CHEMBL105350 |
CHEMBL825457
(1)
|
0 / 3 |
| Q9UQM7 | Calcium/calmodulin-dependent protein kinase type II subunit alpha | Camk2 | CHEMBL105350 |
CHEMBL2148933
(1)
|
0 / 0 |
| P26358 | DNA (cytosine-5)-methyltransferase 1 | Transferase | CHEMBL105350 |
CHEMBL1035628
(1)
|
2 / 0 |
| Q04760 | Lactoylglutathione lyase | Enzyme | CHEMBL105350 |
CHEMBL1670272
(1)
CHEMBL1799085
(1)
|
0 / 0 |
CTD interaction (36)
| compound | gene | gene name | gene description | interaction | interaction type | form |
reference
pmid |
|---|---|---|---|---|---|---|---|
| C034786 | 4363 |
ABCC1
ABC29 ABCC GS-X MRP MRP1 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 | bis(4-hydroxycinnamoyl)methane results in decreased activity of ABCC1 protein |
decreases activity
|
protein |
15885658
|
| C034786 | 1244 |
ABCC2
ABC30 CMOAT DJS MRP2 cMRP |
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 | bis(4-hydroxycinnamoyl)methane results in decreased activity of ABCC2 protein |
decreases activity
|
protein |
15885658
|
| C034786 | 351 |
APP
AAA ABETA ABPP AD1 APPI CTFgamma CVAP PN-II PN2 |
amyloid beta (A4) precursor protein | [bis(4-hydroxycinnamoyl)methane analog co-treated with APP protein] results in increased expression of MGAT3 mRNA |
affects cotreatment
/ increases expression |
protein |
22029407
|
| C034786 | 351 |
APP
AAA ABETA ABPP AD1 APPI CTFgamma CVAP PN-II PN2 |
amyloid beta (A4) precursor protein | [bis(4-hydroxycinnamoyl)methane analog co-treated with APP protein] results in increased expression of TLR2 mRNA |
affects cotreatment
/ increases expression |
protein |
22029407
|
| C034786 | 351 |
APP
AAA ABETA ABPP AD1 APPI CTFgamma CVAP PN-II PN2 |
amyloid beta (A4) precursor protein | [bis(4-hydroxycinnamoyl)methane analog co-treated with APP protein] results in increased expression of TLR3 mRNA |
affects cotreatment
/ increases expression |
protein |
22029407
|
| C034786 | 351 |
APP
AAA ABETA ABPP AD1 APPI CTFgamma CVAP PN-II PN2 |
amyloid beta (A4) precursor protein | [bis(4-hydroxycinnamoyl)methane analog co-treated with APP protein] results in increased expression of TLR4 mRNA |
affects cotreatment
/ increases expression |
protein |
22029407
|
| C034786 | 351 |
APP
AAA ABETA ABPP AD1 APPI CTFgamma CVAP PN-II PN2 |
amyloid beta (A4) precursor protein | [bis(4-hydroxycinnamoyl)methane analog co-treated with APP protein] results in increased expression of VDR mRNA |
affects cotreatment
/ increases expression |
protein |
22029407
|
| C034786 | 351 |
APP
AAA ABETA ABPP AD1 APPI CTFgamma CVAP PN-II PN2 |
amyloid beta (A4) precursor protein | [bis(4-hydroxycinnamoyl)methane co-treated with APP protein] results in increased expression of MGAT3 mRNA |
affects cotreatment
/ increases expression |
protein |
22029407
|
| C034786 | 351 |
APP
AAA ABETA ABPP AD1 APPI CTFgamma CVAP PN-II PN2 |
amyloid beta (A4) precursor protein | [bis(4-hydroxycinnamoyl)methane co-treated with APP protein] results in increased expression of TLR2 mRNA |
affects cotreatment
/ increases expression |
protein |
22029407
|
| C034786 | 351 |
APP
AAA ABETA ABPP AD1 APPI CTFgamma CVAP PN-II PN2 |
amyloid beta (A4) precursor protein | [bis(4-hydroxycinnamoyl)methane co-treated with APP protein] results in increased expression of TLR3 mRNA |
affects cotreatment
/ increases expression |
protein |
22029407
|
| C034786 | 351 |
APP
AAA ABETA ABPP AD1 APPI CTFgamma CVAP PN-II PN2 |
amyloid beta (A4) precursor protein | [bis(4-hydroxycinnamoyl)methane co-treated with APP protein] results in increased expression of TLR4 mRNA |
affects cotreatment
/ increases expression |
protein |
22029407
|
| C034786 | 351 |
APP
AAA ABETA ABPP AD1 APPI CTFgamma CVAP PN-II PN2 |
amyloid beta (A4) precursor protein | bis(4-hydroxycinnamoyl)methane inhibits the reaction [APP protein binds to APP protein] |
affects binding
/ decreases reaction |
protein |
19715544
|
| C034786 | 2730 |
GCLM
GLCLR |
glutamate-cysteine ligase, modifier subunit (EC:6.3.2.2) | bis(4-hydroxycinnamoyl)methane results in increased expression of GCLM mRNA |
increases expression
|
mRNA |
19188863
|
| C034786 | 2730 |
GCLM
GLCLR |
glutamate-cysteine ligase, modifier subunit (EC:6.3.2.2) | bis(4-hydroxycinnamoyl)methane results in increased expression of GCLM protein |
increases expression
|
protein |
19188863
|
| C034786 | 3162 |
HMOX1
HMOX1D HO-1 HSP32 bK286B10 |
heme oxygenase (decycling) 1 (EC:1.14.99.3) | bis(4-hydroxycinnamoyl)methane results in increased expression of HMOX1 mRNA |
increases expression
|
mRNA |
19188863
|
| C034786 | 3162 |
HMOX1
HMOX1D HO-1 HSP32 bK286B10 |
heme oxygenase (decycling) 1 (EC:1.14.99.3) | bis(4-hydroxycinnamoyl)methane results in increased expression of HMOX1 protein |
increases expression
|
protein |
19188863
|
| C034786 | 4248 |
MGAT3
GNT-III GNT3 |
mannosyl (beta-1,4-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase (EC:2.4.1.144) | [bis(4-hydroxycinnamoyl)methane analog co-treated with APP protein] results in increased expression of MGAT3 mRNA |
affects cotreatment
/ increases expression |
mRNA |
22029407
|
| C034786 | 4248 |
MGAT3
GNT-III GNT3 |
mannosyl (beta-1,4-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase (EC:2.4.1.144) | [bis(4-hydroxycinnamoyl)methane co-treated with APP protein] results in increased expression of MGAT3 mRNA |
affects cotreatment
/ increases expression |
mRNA |
22029407
|
| C034786 | 4248 |
MGAT3
GNT-III GNT3 |
mannosyl (beta-1,4-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase (EC:2.4.1.144) | bis(4-hydroxycinnamoyl)methane results in increased expression of MGAT3 mRNA |
increases expression
|
mRNA |
19090986
|
| C034786 | 4323 |
MMP14
MMP-14 MMP-X1 MT-MMP MT-MMP_1 MT1-MMP MT1MMP MTMMP1 WNCHRS |
matrix metallopeptidase 14 (membrane-inserted) (EC:3.4.24.80) | bis(4-hydroxycinnamoyl)methane results in decreased expression of MMP14 protein |
decreases expression
|
protein |
18495463
|
| C034786 | 4313 |
MMP2
CLG4 CLG4A MMP-II MONA TBE-1 |
matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) (EC:3.4.24.24) | bis(4-hydroxycinnamoyl)methane results in decreased secretion of and results in decreased activity of MMP2 protein modified form |
decreases activity
/ decreases secretion |
protein |
18495463
|
| C034786 | 4318 |
MMP9
CLG4B GELB MANDP2 MMP-9 |
matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) (EC:3.4.24.35) | bis(4-hydroxycinnamoyl)methane results in decreased secretion of and results in decreased activity of MMP9 protein |
decreases activity
/ decreases secretion |
protein |
18495463
|
| C034786 | 1728 |
NQO1
DHQU DIA4 DTD NMOR1 NMORI QR1 |
NAD(P)H dehydrogenase, quinone 1 (EC:1.6.5.2) | bis(4-hydroxycinnamoyl)methane results in increased expression of NQO1 mRNA |
increases expression
|
mRNA |
19188863
|
| C034786 | 1728 |
NQO1
DHQU DIA4 DTD NMOR1 NMORI QR1 |
NAD(P)H dehydrogenase, quinone 1 (EC:1.6.5.2) | bis(4-hydroxycinnamoyl)methane results in increased expression of NQO1 protein |
increases expression
|
protein |
19188863
|
| C034786 | 5328 |
PLAU
ATF BDPLT5 QPD UPA URK u-PA |
plasminogen activator, urokinase (EC:3.4.21.73) | bis(4-hydroxycinnamoyl)methane results in decreased secretion of PLAU protein |
decreases secretion
|
protein |
18495463
|
| C034786 | 5468 |
PPARG
CIMT1 GLM1 NR1C3 PPARG1 PPARG2 PPARgamma |
peroxisome proliferator-activated receptor gamma | bis(4-hydroxycinnamoyl)methane binds to PPARG protein |
affects binding
|
protein |
15713005
|
| C034786 | 7077 |
TIMP2
CSC-21K DDC8 |
TIMP metallopeptidase inhibitor 2 | bis(4-hydroxycinnamoyl)methane results in decreased expression of TIMP2 protein |
decreases expression
|
protein |
18495463
|
| C034786 | 7097 |
TLR2
CD282 TIL4 |
toll-like receptor 2 | [bis(4-hydroxycinnamoyl)methane analog co-treated with APP protein] results in increased expression of TLR2 mRNA |
affects cotreatment
/ increases expression |
mRNA |
22029407
|
| C034786 | 7097 |
TLR2
CD282 TIL4 |
toll-like receptor 2 | [bis(4-hydroxycinnamoyl)methane co-treated with APP protein] results in increased expression of TLR2 mRNA |
affects cotreatment
/ increases expression |
mRNA |
22029407
|
| C034786 | 7098 |
TLR3
CD283 IIAE2 |
toll-like receptor 3 | [bis(4-hydroxycinnamoyl)methane analog co-treated with APP protein] results in increased expression of TLR3 mRNA |
affects cotreatment
/ increases expression |
mRNA |
22029407
|
| C034786 | 7098 |
TLR3
CD283 IIAE2 |
toll-like receptor 3 | [bis(4-hydroxycinnamoyl)methane co-treated with APP protein] results in increased expression of TLR3 mRNA |
affects cotreatment
/ increases expression |
mRNA |
22029407
|
| C034786 | 7099 |
TLR4
ARMD10 CD284 TLR-4 TOLL |
toll-like receptor 4 | [bis(4-hydroxycinnamoyl)methane analog co-treated with APP protein] results in increased expression of TLR4 mRNA |
affects cotreatment
/ increases expression |
mRNA |
22029407
|
| C034786 | 7099 |
TLR4
ARMD10 CD284 TLR-4 TOLL |
toll-like receptor 4 | [bis(4-hydroxycinnamoyl)methane co-treated with APP protein] results in increased expression of TLR4 mRNA |
affects cotreatment
/ increases expression |
mRNA |
22029407
|
| C034786 | 7421 |
VDR
NR1I1 |
vitamin D (1,25- dihydroxyvitamin D3) receptor | [bis(4-hydroxycinnamoyl)methane analog co-treated with APP protein] results in increased expression of VDR mRNA |
affects cotreatment
/ increases expression |
mRNA |
22029407
|
| C034786 | 7490 |
WT1
AWT1 EWS-WT1 GUD NPHS4 WAGR WIT-2 WT33 |
Wilms tumor 1 | bis(4-hydroxycinnamoyl)methane results in decreased expression of WT1 mRNA |
decreases expression
|
mRNA |
18034345
|
| C034786 | 7490 |
WT1
AWT1 EWS-WT1 GUD NPHS4 WAGR WIT-2 WT33 |
Wilms tumor 1 | bis(4-hydroxycinnamoyl)methane results in decreased expression of WT1 protein |
decreases expression
|
protein |
18034345
|
Related Disease
Diseases related to proteins in ChEMBL interactions
Diseases related to CTD interactions
4 disease from interactions of metabolites
| MeSH disease | OMIM | compound | disease name | evidence type |
reference
pmid |
|---|---|---|---|---|---|
| D000544 | C034786 | Alzheimer Disease |
therapeutic
|
19090986
|
|
| D004487 | C034786 | Edema |
therapeutic
|
18449507
|
|
| D009361 | C034786 | Neoplasm Invasiveness |
therapeutic
|
18495463
|
|
| D013276 | C034786 | Stomach Ulcer |
therapeutic
|
19188055
|